QIAGEN Launches QIAsymphony Connect for Automated Clinical Nucleic Acid Extraction
QIAGEN has announced the commercial launch of QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. Building on the trusted QIAsymphony platform, with more than 3,300 cumulative placements worldwide, the new system helps clinical laboratories standardize extraction across diverse assay workflows. The platform delivers highly concentrated DNA and RNA for sensitive downstream assays, supporting reliable detection across clinical molecular testing applications including liquid biopsy, oncology, and infectious disease diagnostics.
QIAsymphony Connect supports routine clinical molecular testing through several key capabilities. Integrated liquid handling, prefilled IVD reagent cartridges, automated load checks, and guided workflow setup minimize run-to-run and operator-to-operator variability, enabling standardized walkaway workflows with less hands-on time while supporting reproducible nucleic acid extraction. Automated barcode reading of primary sample tubes and eluates, built-in audit trails, and onboard process controls provide complete sample traceability and strengthen process safety throughout the extraction workflow. Processing up to 96 samples in four independent batches supports routine laboratory productivity, with sample input volumes ranging from a few microliters up to 10 mL delivering highly concentrated DNA and RNA for sensitive downstream applications including liquid biopsy, which requires detection of often low-abundance molecular targets circulating in blood.
QIAsymphony Connect introduces enhanced usability, digital connectivity, and workflow standardization while maintaining full backward compatibility with trusted QIAsymphony reagent kits and consumables. Their continued use across both platforms facilitates a smoother and faster migration to the new system. Laboratories implementing new molecular testing applications benefit from workflow enhancements designed to simplify routine operation and support standardized molecular testing.
Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN, said clinical laboratories need automation solutions that combine proven extraction performance with the standardization, traceability, and productivity needed for today’s molecular testing workflows. Sood noted that the commercial launch of QIAsymphony Connect reflects QIAGEN’s continued investment in automated sample preparation and strengthens the Sample to Insight portfolio by helping laboratories improve consistency and efficiency across clinical molecular testing.
QIAGEN has completed FDA listing in the United States and EUDAMED listing in Europe, accomplishing significant regulatory milestones as the platform enters broader commercial availability. The company has already received initial customer orders, reflecting early market adoption. Early users have highlighted the platform’s intuitive guided workflow setup, comprehensive sample traceability, and reduced hands-on time as important advantages, along with the consistency of nucleic acid extraction and simplified run setup across both established and newly implemented molecular testing workflows.
